Unusual Gingival Presentation Following Treatment With Pembrolizumab: A Case Report

Immune checkpoint PD-1 inhibitors such as pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) has demonstrated efficacy in second-line therapy for relapsed/refractory classical Hodgkin lymphoma (cHL). Although generally well tolerated, pembrolizumab could lead to immune-related adverse events (irAEs) such as rash, fatigue, hyperthyroidism, pneumonitis, hepatitis, and colitis. Oral irAEs are not uncommon among immune checkpoint inhibitors which include xerostomia, dysgeusia, lichenoid reactions and mucositis.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research